JP2021528415A - オデビキシバットの医薬製剤 - Google Patents
オデビキシバットの医薬製剤 Download PDFInfo
- Publication number
- JP2021528415A JP2021528415A JP2020570778A JP2020570778A JP2021528415A JP 2021528415 A JP2021528415 A JP 2021528415A JP 2020570778 A JP2020570778 A JP 2020570778A JP 2020570778 A JP2020570778 A JP 2020570778A JP 2021528415 A JP2021528415 A JP 2021528415A
- Authority
- JP
- Japan
- Prior art keywords
- odebicibat
- preparation according
- particles
- suspension
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 13
- 229940127557 pharmaceutical product Drugs 0.000 title abstract description 8
- 239000002245 particle Substances 0.000 claims abstract description 117
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 238000009472 formulation Methods 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 41
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 34
- 239000003613 bile acid Substances 0.000 claims abstract description 27
- 208000019423 liver disease Diseases 0.000 claims abstract description 21
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 20
- 230000001419 dependent effect Effects 0.000 claims abstract description 4
- 239000013078 crystal Substances 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 239000000725 suspension Substances 0.000 claims description 50
- 230000009466 transformation Effects 0.000 claims description 47
- 239000002775 capsule Substances 0.000 claims description 38
- 238000000576 coating method Methods 0.000 claims description 37
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 36
- 239000011248 coating agent Substances 0.000 claims description 32
- 229920000642 polymer Polymers 0.000 claims description 20
- 239000011247 coating layer Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 238000001238 wet grinding Methods 0.000 claims description 10
- 239000007900 aqueous suspension Substances 0.000 claims description 9
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 6
- 201000005271 biliary atresia Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010008635 Cholestasis Diseases 0.000 abstract description 15
- 230000007870 cholestasis Effects 0.000 abstract description 15
- 231100000359 cholestasis Toxicity 0.000 abstract description 15
- 201000011374 Alagille syndrome Diseases 0.000 abstract description 5
- 210000003445 biliary tract Anatomy 0.000 abstract description 5
- 230000035772 mutation Effects 0.000 description 31
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 18
- 238000000113 differential scanning calorimetry Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 101000701363 Homo sapiens Phospholipid-transporting ATPase IC Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 102100030448 Phospholipid-transporting ATPase IC Human genes 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 102000001479 Member 11 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 10
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 229940088679 drug related substance Drugs 0.000 description 9
- 238000001374 small-angle light scattering Methods 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 229960003943 hypromellose Drugs 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 102100038495 Bile acid receptor Human genes 0.000 description 5
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 5
- 101000955481 Homo sapiens Phosphatidylcholine translocator ABCB4 Proteins 0.000 description 5
- 101000785523 Homo sapiens Tight junction protein ZO-2 Proteins 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 101150005380 Myo5b gene Proteins 0.000 description 5
- 102100039032 Phosphatidylcholine translocator ABCB4 Human genes 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 102100026637 Tight junction protein ZO-2 Human genes 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100028282 Bile salt export pump Human genes 0.000 description 4
- 101000724352 Homo sapiens Bile salt export pump Proteins 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 235000017284 Pometia pinnata Nutrition 0.000 description 4
- 240000007653 Pometia tomentosa Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102220505876 Bile salt export pump_R1153C_mutation Human genes 0.000 description 3
- 102220505883 Bile salt export pump_R1268Q_mutation Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102220580017 Phospholipid-transporting ATPase IC_G1040R_mutation Human genes 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 239000002178 crystalline material Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 235000013572 fruit purees Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000008185 minitablet Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 101150048692 ABCB11 gene Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 229940121471 odevixibat Drugs 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- FOVHHEATXDRFTQ-UHFFFAOYSA-N O.O.C(C)O.C(C)O.C(C)O Chemical compound O.O.C(C)O.C(C)O.C(C)O FOVHHEATXDRFTQ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 101150063830 abcB4 gene Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000031200 bile acid secretion Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002603 extrahepatic bile duct Anatomy 0.000 description 1
- 208000019298 familial intrahepatic cholestasis Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Liquid Crystal Substances (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本出願は、2018年6月20日に出願したスウェーデン特許出願第1850761-6号、及び2018年6月20日に出願したスウェーデン特許出願第1850762-4号(これらの開示は、参照によりそれらの全体が本明細書に組み込まれている)の優先権を主張するものである。
・ PFIC 1型は、「バイラー病」と呼ばれることもあり、胆管内の細胞膜中のリン脂質として知られる脂肪の適正な均衡を維持するのを助けるタンパク質をコードする、ATP8B1遺伝子の変異に起因する胆汁分泌の障害によって引き起こされる。これらのリン脂質の不均衡は、胆汁うっ滞及び肝臓内の胆汁酸の上昇と関連している。PFIC 1型に罹患した対象は、通常、生後1か月で胆汁うっ滞を発症し、外科的治療がなければ、生後10年が過ぎる前に肝硬変及び末期肝疾患に進行する。
・ PFIC 2型は、「バイラー症候群」と呼ばれることもあり、胆汁酸を肝臓外に移動させる胆汁酸塩排出ポンプとして知られるタンパク質をコードする、ABCB11遺伝子の変異に起因する胆汁酸塩分泌の障害によって引き起こされる。PFIC 2型を有する対象は、生後数年以内に肝不全を発症することが多く、肝細胞癌として知られる、ある種の肝臓がんを発症するリスクが高い。
・ PFIC 3型は、典型的には、小児期の最初の数年に進行性胆汁うっ滞と共に現れ、細胞膜を横切ってリン脂質を移動させる輸送体をコードするABCB4遺伝子の変異によって引き起こされる。
a)ホモジナイザを使用してオデビキシバットを水中で湿らせる工程;及び
b)湿ったオデビキシバットを湿式粉砕によって水中に分散させ、それによってオデビキシバットの均質な水性懸濁液を得る工程
を含む。
本明細書で使用される場合、「治療」、「治療する」、及び「治療すること」という用語は、本明細書に記載する通りの疾患、又は障害、又はそれらの1つ若しくは複数の症状の後退、緩和、それらの発症の遅延、又はそれらの進行の阻害を指す。幾つかの実施形態では、治療は、1つ又は複数の症状が発症した後に施されてもよい。他の実施形態では、治療は、症状の非存在下で施されてもよい。例えば、治療は、罹患しやすい個体に(例えば、症状の病歴を考慮して、及び/又は遺伝的若しくは他の罹患しやすい要因を考慮して)、症状の発症前に施されてもよい。治療は、症状が解消した後でも、例えば、その再発を予防又は遅延させるために継続されてもよい。
DMF ジメチルホルムアミド
DMSO ジメチルスルホキシド
EtOH エタノール
MeOH メタノール
RH 相対湿度
2-PrOH 2-プロパノール
X線粉末回折(XRPD)分析
分析は、CuロングファインフォーカスX線管及びPIXcel検出器を備えたPANalytical X'Pert Pro回折計を用いて22℃で行った。自動発散及び散乱防止スリットを、0.02radのSollerスリット及びNiフィルターと一緒に使用した。乾燥試料を、切り出したシリコンのZero Background Holder(ZBH)上に塗抹し、2〜40°(2θ)の間で、17分の分析時間で分析した。すべてのスラリー試料を熱処理した多孔質アルミナフィルター基板上に滴下し、それらが乾くにつれて2回分析し、最初に1分16秒の走査(2〜30°(2θ))、次いで7分の走査(2〜30°(2θ))を行った。最後の17分の走査は、試料が数時間乾燥したときに行った。
管の張力及び電流:40kV、50mA
波長アルファ1(CuKα1):1.5406Å
波長アルファ2(CuKα2):1.5444Å
波長アルファ1とアルファ2の平均(CuKα):1.5418Å
実験は、TA Instruments社Q2000 Differential Scanning Calorimeterを使用して行った。使用したDCSるつぼは、蓋にピンホール(直径≧0.2mm)を有するTZeroアルミニウムパンであった。測定を通して50mL/分の一定流量での乾燥窒素パージをDSCセル内で維持した。
製剤の調製(小規模)
微結晶性セルロース球を、以下のTable 5(表5)に示す通りの異なる2つのオデビキシバットのコーティング懸濁液のうちの1つでコーティングして、0.5%w/w又は1.5%w/wのオデビキシバットのいずれかを含有する粒子を得た。
オデビキシバット原薬を含有するコーティング懸濁液は、以下の3つの工程で調製した:
a)オデビキシバットの懸濁液:オデビキシバット原薬を0.5mmのふるいを通してふるい分けし、続いてホモジナイザを使用して(Ultra Turrax T25;およそ6600〜7000rpmで15分)少量の水中で湿らせた。次いで、得られた湿ったオデビキシバット原薬を、コロイドミルを用いて(IKA社Magic Lab MKO又はMKモジュール、14600rpmで20分間、ギャップサイズ1.5回転)水中に分散させ、凝集粒子のレベルが工程内管理の合格限界を満たすまで行った。
b)ヒプロメロースの分散体:ヒプロメロース(3mPa.s)を熱水中に混合しながら分散させ、得られた分散体を室温まで冷却した。
c)オデビキシバットのコーティング懸濁液:コロイドミル内でヒプロメロースの分散体をオデビキシバットの懸濁液に添加し、この懸濁液を4分間10000rpmで混合した。最終的な混合を低速で磁気撹拌器を使用して継続した。オデビキシバットのコーティング懸濁液は、コーティングプロセスに使用する前に0.5mmのふるいを通してろ過した。
微結晶性セルロース(MCC)球は、ウルスター挿入物を有する流動床コーティング機内で、オデビキシバットのコーティング懸濁液を使用してコーティングした。MCC球上のコーティング懸濁液の量は、秤量によって決定する。微粒子だけでなく二重体を除去するために、コーティング済み粒子は、0.5mm及び1.25mmのふるいをそれぞれ通してふるい分けした。次いで粒子をバルクコンテナに移し、医薬品中間体として取り扱った。
各々の単位用量に必要とされる計算量の粒子を、ハードヒドロキシプロピルメチルセルロース(HPMC)カプセル(サイズ0又はサイズ3)中に自動カプセル充填器を使用して充填して、4つの異なる力価:200、400、600、及び1200μgを得た。
製剤の調製(大規模化)
微結晶性セルロース球を、以下のTable 7(表7)に示す通りの異なる2つのオデビキシバットのコーティング懸濁液のうちの1つでコーティングして、0.5%w/w又は1.5%w/wのオデビキシバットのいずれかを含有する粒子を得た。
オデビキシバット原薬を含有するコーティング懸濁液は、以下の3つの工程で調製した:
a)オデビキシバットの懸濁液:オデビキシバット原薬を、ホモジナイザを使用して(Ultra Turrax T25;およそ6600〜7000rpmで15分)少量の水中で湿らせた。次いで、得られた湿ったオデビキシバット原薬を、コロイドミルを用いて(IKA社Magic Lab MKO又はMKモジュール、14600rpmで20分間、ギャップサイズ1.5回転)水中に分散させ、凝集粒子のレベルが工程内管理の合格限界、すなわち、d90<12μm(低角度レーザー光散乱(LALLS)によって決定したとき)を満たすまで行った。
b)ヒプロメロースの分散体:ヒプロメロース(3mPa.s)を熱水中に混合しながら分散させ、得られた分散体を室温まで冷却した。
c)オデビキシバットのコーティング懸濁液:ヒプロメロースの分散体をオデビキシバットの懸濁液に添加し、この懸濁液を混合した。最終的な混合を低速で撹拌器を使用して継続した。オデビキシバットのコーティング懸濁液は、コーティングプロセスに使用する前に0.5mmのふるいを通してろ過した。
得られたオデビキシバットのコーティング懸濁液を、実施例1に記載するコーティングプロセスに従って、微結晶性セルロース(MCC)球をコーティングするのに使用した。
カプセルを、実施例1に従って調製した。様々なカプセルの力価についての充填質量、オデビキシバット及び他の成分の量、並びにカプセルのサイズは、上のTable 5(表5)に提示した。
結晶変態1の調製
無水アルコール(100.42kg)及び粗オデビキシバット(18.16kg)を250LのGLRに窒素雰囲気下で撹拌しながら装入した。精製水(12.71kg)を添加し、反応物を25±5℃で15分間窒素雰囲気下で撹拌した。撹拌を25±5℃で3〜60分間、透明な溶液が形成されるまで継続した。溶液を、5.0μのSSカートリッジフィルター、続いて0.2μのPPカートリッジフィルターを通してろ過し、次いで清浄な反応器に移した。精製水(63.56kg)を25±5℃で2〜3時間にわたってゆっくり添加し、溶液にオデビキシバットの結晶変態1を種晶添加した。溶液を25±5℃で12時間撹拌した。この時間の間に、溶液は濁りを生じた。析出した固体を、遠心分離機を通してろ過し、材料を30分間遠心脱水した。材料を、その後Nutscheフィルター中で12時間真空乾燥させた。次いで材料を、真空棚段乾燥器中、25±5℃、真空下(550mmHg)で10時間、次いで30±5℃、真空下(550mmHg)で16時間乾燥させた。材料をオフホワイトの結晶性固体として単離した。単離した結晶性材料を粉砕し、LDPEの袋に保存した。
エタノール及び水からの結晶変態2の調製
105.9mgのオデビキシバットを計量して1mLのChromacol容器に入れた。磁気撹拌子及び1.0mLのエタノール:水の70:30%v/v混合物を添加し、容器をクリンプキャップで閉じた。次いで、得られたスラリーを25℃で1週間撹拌したままにした。
示差走査熱量測定による結晶分画の決定
この方法は、部分的に結晶性の試料におけるオデビキシバット原薬の結晶分画を定量化する。定量化は、部分的に結晶性の試料がオデビキシバットの結晶性水和物と非晶相との二成分混合物であるという仮定に基づいている。結晶分画は、無水形の融解エンタルピーに基づいて定量化される。この無水形は、水和物を昇温で乾燥させることによって自発的且つ再現可能に形成する、脱水した水和物である。
サイクル1: 5℃/分の走査速度で20℃から120℃への温度の増加;
サイクル2: 10℃/分の走査速度で120℃から80℃への温度の減少;及び
サイクル3: 10℃/分の走査速度で80℃から200℃への温度の増加。
LALLSによってモニタリングされる均質性
オデビキシバットのコーティング懸濁液の均質性を、低角度レーザー光散乱(LALLS)を使用して試験した。0.5%w/wのオデビキシバットを含有する粒子にするための3つのオデビキシバットのコーティング懸濁液を、オデビキシバット原薬(16g)をUltra Turraxホモジナイザで水(200g)中に7分間分散することによって生成した。原薬が分散したら、ホモジナイザを追加的に8分運転した。次いでホモジナイザを水(216g)ですすぎ、それを懸濁液に添加した。
含量均一性
2つの異なる力価、0.5%w/w及び1.5%w/wのペレットを、実施例1に記載する通りに調製した。カプセル中のオデビキシバットの量を、逆相高速液体クロマトグラフィ(RP-HPLC)を使用して、30個のカプセルについて決定した。移動相:40:60 アセトニトリル:酢酸塩緩衝液pH5.5;流量1.5mL/分;カラム:Zorbax SB-CN(50×4.6mm、3.5μm)。オデビキシバットのアッセイ量及び含量均一性をTable 10(表10)に提示する。
低pHでの安定性試験
0.5%w/wのオデビキシバットを含有する約40mgのコーティング済み粒子(200μgのカプセル1個の含量に相当する)を大さじ1杯の食品上に振りかけ、120分間での回収率を決定することによって、オデビキシバットでコーティングされた粒子と、ヨーグルト、リンゴソース、又は果実ピューレの間の適合性を評価した。オデビキシバットの回収率は、逆相高速液体クロマトグラフィ(RP-HPLC)法を使用して決定した。移動相:40:60 アセトニトリル:酢酸塩緩衝液pH5.5;流量1.5mL/分;カラム:Zorbax SB-CN(50×4.6mm、3.5μm)。
長期安定性試験
実施例1に従って調製したサイズ0及びサイズ3のオデビキシバットのカプセルを、HDPEのキャップを有するHDPEのボトル内に保存し、長期保存条件として25℃及び相対湿度60%で、並びに加速条件として40℃及び相対湿度75%で保持した。オデビキシバット、関連物質、及び水の量を、25℃/60%RHで保存した試料については1、3、6、9、及び12か月後に、40℃/75%RHで保存した試料については1、3、及び6か月後に決定した。力価200μg(サイズ0)のカプセルについての結果をTable 15(表15)に、力価600μg(サイズ0)のカプセルについての結果をTable 16(表16)に、力価400μg(サイズ3)のカプセルについての結果をTable 17(表17)に、そして力価1200μg(サイズ3)のカプセルについての結果をTable 18(表18)に提示する。
ペレットの混合均一性
2つの異なる力価、0.5%w/w及び1.5%w/wの粒子を、実施例2に記載する通りに調製した。ふるい分けしたペレットを、PEバッグで裏打ちされた55Lのドラム内に収集した。ペレットを、ドラムの異なる10箇所から0.25mLの試料採取器先端部でサンプリングした。各々の場所からの平均試料は80mgであり、これは、200μg若しくは600μgのサイズ0のカプセル2個の含量、又は400μg又は1200μgのサイズ3のカプセル1個の含量に相当する。オデビキシバットの含量は、RP-UPLCによって決定した:移動相A:80:20 酢酸アンモニウム緩衝液pH5.7/アセトニトリル;移動相B:20:80 酢酸アンモニウム緩衝液pH5.7/アセトニトリル;流量0.40mL/分;カラム:Waters社Acquity BEH C8 100×2.1mm、1.7mm;勾配:0分:60%A:40%B、12分:20%A:80%B、13.5分:20%A:80%B、13.6分:60%A:40%B、15分:60%A:40%B。オデビキシバットのアッセイ量及び含量均一性をTable 19(表19)に提示する。
Claims (33)
- 複数の粒子を含むオデビキシバットの医薬製剤であって、各々の粒子が、約0.1〜約1.5mmの間のサイズであり、粒子の総質量に対して約0.1%w/w〜約5.0%w/wの量でオデビキシバット又は医薬として許容されるその塩を含有する、医薬製剤。
- 各々の粒子が、粒子の総質量に対して約0.5%w/w〜約2.0%w/wの量でオデビキシバット又は医薬として許容されるその塩を含有する、請求項1に記載の製剤。
- 各々の粒子が、粒子の総質量に対して約0.5%w/wの量でオデビキシバット又は医薬として許容されるその塩を含有する、請求項1又は2に記載の製剤。
- 各々の粒子が、粒子の総質量に対して約1.5%w/wの量でオデビキシバット又は医薬として許容されるその塩を含有する、請求項1又は2に記載の製剤。
- 各々の粒子が、コアと、コアを取り囲むコーティング層とを含む、請求項1から4のいずれか一項に記載の製剤。
- コアがオデビキシバットを含有しない、請求項5に記載の製剤。
- コアが微結晶性セルロースを含む、請求項5又は6に記載の製剤。
- コーティング層が、オデビキシバット又は医薬として許容されるその塩を含む、請求項5から7のいずれか一項に記載の製剤。
- コーティング層が、皮膜形成ポリマーを更に含む、請求項5から8のいずれか一項に記載の製剤。
- コーティング層が、オデビキシバットの均質な水中懸濁液として粒子上に噴霧されている、請求項5から9のいずれか一項に記載の製剤。
- 均質な懸濁液が、オデビキシバットを湿式粉砕によって水中に分散させることによって調製される、請求項10に記載の製剤。
- 均質な懸濁液が、200μmより大きいオデビキシバットの凝集粒子を含有しない、請求項10又は11に記載の製剤。
- コーティング層が界面活性剤を含有しない、請求項5から12のいずれか一項に記載の製剤。
- 粒子が約0.1〜約1.0mmの間のサイズである、請求項1から13のいずれか一項に記載の製剤。
- オデビキシバットが、オデビキシバットの結晶性水和物として存在する、請求項1から14のいずれか一項に記載の製剤。
- オデビキシバットが、オデビキシバットの結晶変態1として存在する、請求項1から15のいずれか一項に記載の製剤。
- オデビキシバットの結晶変態1が、CuKα1線で得られた、°2θ位置5.6±0.2、6.7±0.2、及び/又は12.1±0.2に少なくとも特定のピークを有するX線粉末回折(XRPD)パターンを有する、請求項16に記載の製剤。
- 粒子が、サシェ又はカプセル中に含有される、請求項1から17のいずれか一項に記載の製剤。
- 小児製剤である、請求項1から18のいずれか一項に記載の製剤。
- 肝疾患の治療又は予防に使用するための、請求項1から19のいずれか一項に記載の製剤。
- 肝疾患が胆汁酸依存性疾患である、請求項20に記載の製剤。
- 肝疾患が進行性家族性肝内胆汁うっ滞(PFIC)である、請求項20に記載の製剤。
- 肝疾患が胆道閉鎖である、請求項20に記載の製剤。
- オデビキシバットの均質な水性懸濁液を調製する工程を含む、請求項1から19のいずれか一項に記載の医薬製剤を調製するための方法。
- コーティング懸濁液が、オデビキシバットを湿式粉砕によって水中に分散させることによって調製される、請求項24に記載の方法。
- コーティング懸濁液が、200μmより大きいオデビキシバットの凝集粒子を含有しない、請求項24又は25に記載の方法。
- コーティング懸濁液が界面活性剤を含有しない、請求項24から26のいずれか一項に記載の方法。
- 請求項1から19のいずれか一項に記載の製剤を調製するための方法であって、
a)ホモジナイザを使用してオデビキシバットを水中で湿らせる工程;及び
b)湿ったオデビキシバットを湿式粉砕によって水中に分散させ、それによってオデビキシバットの均質な水性懸濁液を得る工程
を含む方法。 - 皮膜形成ポリマーが、工程(b)で得られた懸濁液に添加される、請求項18に記載の方法。
- オデビキシバットが、オデビキシバットの結晶性水和物として存在する、請求項24から29のいずれか一項に記載の方法。
- オデビキシバットが、オデビキシバットの結晶変態1として存在する、請求項24から29のいずれか一項に記載の方法。
- オデビキシバットの結晶変態1が、CuKα1線で得られた、°2θ位置5.6±0.2、6.7±0.2、及び/又は12.1±0.2に少なくとも特定のピークを有するX線粉末回折(XRPD)パターンを有する、請求項31に記載の方法。
- 請求項24から32のいずれか一項に記載の方法によって得られる製剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1850761-6 | 2018-06-20 | ||
SE1850761 | 2018-06-20 | ||
SE1850762-4 | 2018-06-20 | ||
SE1850762 | 2018-06-20 | ||
PCT/SE2019/050603 WO2019245449A1 (en) | 2018-06-20 | 2019-06-20 | Pharmaceutical formulation of odevixibat |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021528415A true JP2021528415A (ja) | 2021-10-21 |
JPWO2019245449A5 JPWO2019245449A5 (ja) | 2022-06-23 |
JP7448490B2 JP7448490B2 (ja) | 2024-03-12 |
Family
ID=67138007
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020570778A Active JP7448490B2 (ja) | 2018-06-20 | 2019-06-20 | オデビキシバットの医薬製剤 |
JP2020570784A Pending JP2021528416A (ja) | 2018-06-20 | 2019-06-20 | オデビキシバットの結晶変態 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020570784A Pending JP2021528416A (ja) | 2018-06-20 | 2019-06-20 | オデビキシバットの結晶変態 |
Country Status (21)
Country | Link |
---|---|
US (4) | US11802115B2 (ja) |
EP (2) | EP3810581A1 (ja) |
JP (2) | JP7448490B2 (ja) |
KR (2) | KR20210024033A (ja) |
CN (2) | CN112262130A (ja) |
AU (2) | AU2019290338A1 (ja) |
BR (2) | BR112020024479A2 (ja) |
CA (2) | CA3100687A1 (ja) |
CL (2) | CL2020003296A1 (ja) |
CO (2) | CO2020015772A2 (ja) |
CR (2) | CR20210027A (ja) |
EC (2) | ECSP21000999A (ja) |
IL (2) | IL279464A (ja) |
JO (2) | JOP20200297A1 (ja) |
MX (2) | MX2020013839A (ja) |
NI (2) | NI202000103A (ja) |
PE (2) | PE20210136A1 (ja) |
PH (2) | PH12020552165A1 (ja) |
SG (2) | SG11202012151XA (ja) |
TW (1) | TWI823954B (ja) |
WO (2) | WO2019245448A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013010157B1 (pt) | 2010-11-08 | 2020-02-04 | Albireo Ab | iinibidores do ibat, seus usos, e composição e combinações farmacêuticas |
CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
ES2942443T3 (es) | 2018-06-05 | 2023-06-01 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CN112262130A (zh) | 2018-06-20 | 2021-01-22 | 阿尔比里奥公司 | 奥德昔巴特的结晶修饰物 |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
PL4069360T3 (pl) | 2019-12-04 | 2024-04-29 | Albireo Ab | Związki benzotio(di)azepinowe i ich zastosowanie jako modulatory kwasów żółciowych |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
EP4188541A1 (en) | 2020-08-03 | 2023-06-07 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
AU2021390172A1 (en) | 2020-12-04 | 2023-06-22 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2022166680A1 (zh) * | 2021-06-25 | 2022-08-11 | 苏州科睿思制药有限公司 | 奥德昔巴特的晶型及其制备方法和用途 |
CN113913436B (zh) * | 2021-11-18 | 2023-09-29 | 天津市肿瘤医院(天津医科大学肿瘤医院) | 逆转录转座基因l1-atp8b1及其作为肺鳞癌标志物的用途和治疗肺鳞癌的药物 |
WO2023174937A1 (en) | 2022-03-16 | 2023-09-21 | Sandoz Ag | Particles comprising non-crystalline odevixibat |
WO2024094841A1 (en) | 2022-11-03 | 2024-05-10 | Albireo Ab | Treating alagille syndrome (algs) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013541584A (ja) * | 2010-11-08 | 2013-11-14 | アルビレオ アクチエボラグ | 肝疾患の処置用のibat阻害剤 |
JP2013545739A (ja) * | 2010-11-08 | 2013-12-26 | アルビレオ アクチエボラグ | Ibat阻害剤および胆汁酸結合剤を含む薬学的組み合わせ |
JP2014532662A (ja) * | 2011-10-28 | 2014-12-08 | ルメナ ファーマシューティカルズ,インク. | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
Family Cites Families (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539380A (en) | 1968-01-08 | 1970-11-10 | Upjohn Co | Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms |
GB1566609A (en) | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
GB1573487A (en) | 1977-05-23 | 1980-08-28 | Bristol Myers Co | Bile acid binding composition |
EP0019115B1 (de) | 1979-04-30 | 1983-01-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pankreozymin-Cholezystokinin aktive Peptide, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel |
CA1313135C (en) | 1987-02-09 | 1993-01-26 | The Dow Chemical Company | Cholestyramine composition and process for its preparation |
US5167965A (en) | 1987-02-09 | 1992-12-01 | The Dow Chemical Company | Palatable cholestyramine granules, tablets and methods for preparation thereof |
US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
JP2800242B2 (ja) | 1989-03-30 | 1998-09-21 | 大正製薬株式会社 | 粒剤の製造方法 |
DE3930168A1 (de) | 1989-09-09 | 1991-03-14 | Knoll Ag | Verbesserte verabreichungsform fuer colestyramin |
IL95574A (en) | 1989-09-09 | 1994-11-11 | Knoll Ag | Colstiramine preparation |
GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
JP2542122B2 (ja) * | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | 球状核、球形顆粒およびその製造方法 |
US5250524A (en) | 1990-12-06 | 1993-10-05 | Hoechst Aktiengesellschaft | Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals |
ES2087422T3 (es) | 1991-12-20 | 1996-07-16 | Hoechst Ag | Polimeros y oligomeros de derivados de acidos biliares, procedimiento para su preparacion y su empleo como medicamento. |
JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
IT1257793B (it) | 1992-05-18 | 1996-02-13 | Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato | |
CA2137265C (en) | 1992-06-04 | 2003-10-28 | Sanjay Bhardwaj | Palatable pharmaceutical compositions |
ATE160783T1 (de) | 1992-06-12 | 1997-12-15 | Hoechst Ag | Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel |
US5350584A (en) | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
PT621032E (pt) | 1993-04-23 | 2001-01-31 | Novartis Ag | Dispositivo de distribuicao de libertacao controlada de farmaco |
EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
TW289757B (ja) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
TW289020B (ja) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
TW289021B (ja) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
JP3304093B2 (ja) | 1994-09-13 | 2002-07-22 | モンサント カンパニー | 回腸の胆汁酸輸送及びタウロコール酸塩吸収の阻害活性を有する新規ベンゾチエピン類 |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
EP0893949B1 (en) | 1996-01-16 | 2005-04-27 | Ronald J. Sokol | Use of antioxidant agents to treat cholestatic liver disease |
DE19608592A1 (de) | 1996-03-06 | 1997-09-11 | Hoechst Ag | Antikörper zur selektiven immunologischen Bestimmung von Gallensäuren in biologischen Matrices |
WO1997033882A1 (en) | 1996-03-11 | 1997-09-18 | G.D. Searle And Co. | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
ES2306459T3 (es) | 1996-05-23 | 2008-11-01 | Novartis Ag | Prevencion y tratamiento de adenoma colonico o microadenoma colonico mediante acido 6-fluoroursodesoxicolico (6-fudca). |
EP0912861B1 (de) | 1996-07-24 | 2000-11-29 | Zumtobel Staff GmbH | Adapter für ein haltemittel, welches zum befestigen einer einbauleuchte in einer einbauöffnung bestimmt ist, oder haltemittel oder einbauleuchte mit einem solchen adapter |
DE19633268A1 (de) | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung |
GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
EP0971744A2 (en) | 1997-03-11 | 2000-01-19 | G.D. SEARLE & CO. | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS |
ATE242258T1 (de) | 1997-03-14 | 2003-06-15 | Aventis Pharma Gmbh | Hypolipidemische 1,4-benzothiazepin-1,1-dioxide |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
JP4083818B2 (ja) | 1997-06-06 | 2008-04-30 | ディポメド,インコーポレイティド | 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形 |
WO1998056757A1 (fr) | 1997-06-11 | 1998-12-17 | Sankyo Company, Limited | Derives de benzylamine |
AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
US5900233A (en) | 1997-10-16 | 1999-05-04 | Day; Charles E. | Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome |
US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
RU2236406C2 (ru) | 1997-12-19 | 2004-09-20 | Г.Д. Серл Энд Ко. | Способ получения энантиомерно-обогащенных тетрагидробензотиепиноксидов |
GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
CA2325736A1 (en) | 1998-04-24 | 1999-11-04 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
US6355672B1 (en) | 1998-08-07 | 2002-03-12 | Takeda Chemical Industries, Ltd. | Benzothiepin derivatives, process for the preparation of the same and uses thereof |
IL143947A0 (en) | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
NZ512536A (en) | 1998-12-23 | 2003-11-28 | G | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
JP2002533414A (ja) | 1998-12-23 | 2002-10-08 | ジー.ディー.サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ |
WO2000038725A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations for cardiovascular indications |
NZ512533A (en) | 1998-12-23 | 2004-02-27 | G | A combination of IBAT inhibitor and nicotinic acid derivative to treat hypercholesterolemia, hyperlipidemic or atherosclerotic conditions |
AU3694600A (en) | 1999-02-12 | 2000-08-29 | G.D. Searle Llc | Novel 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
DE19915420A1 (de) | 1999-04-06 | 2000-10-12 | Basf Ag | Stabilisierte Polyvinylpyrrolidon-Zubereitungen |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
US20020054903A1 (en) | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
AU1302301A (en) | 1999-11-08 | 2001-06-06 | Sankyo Company Limited | Nitrogenous heterocycle derivatives |
GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
WO2001060807A1 (en) | 2000-02-18 | 2001-08-23 | Merck & Co. Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
US20020061888A1 (en) | 2000-03-10 | 2002-05-23 | Keller Bradley T. | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
US6794544B2 (en) | 2000-03-10 | 2004-09-21 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
TWI241195B (en) | 2000-04-10 | 2005-10-11 | Shionogi & Co | Preventive agent for bile acidic diarrhea |
US6638498B2 (en) | 2000-06-30 | 2003-10-28 | Semorex Inc. | Molecularly imprinted polymers for the treatment and diagnosis of medical conditions |
US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
AU8969901A (en) | 2000-07-28 | 2002-02-13 | Hoffmann La Roche | New pharmaceutical composition |
FR2812886B1 (fr) | 2000-08-08 | 2002-11-08 | Assist Publ Hopitaux De Paris | Depistage d'un nouveau syndrome hepatique et ses applications |
SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002053548A1 (en) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Benzothiazepine derivatives |
US6506921B1 (en) | 2001-06-29 | 2003-01-14 | Virginia Tech Intellectual Properties, Inc. | Amine compounds and curable compositions derived therefrom |
US20040077625A1 (en) | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
US20040038862A1 (en) | 2001-07-30 | 2004-02-26 | Goodwin Bryan James | Identification of new therapeutic targets for modulating bile acid synthesis |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
RU2305681C2 (ru) * | 2001-09-08 | 2007-09-10 | Астразенека Аб | Производные бензотиадиазепина, способ их получения (варианты) |
US20030199515A1 (en) | 2001-09-12 | 2003-10-23 | G.D. Searle, Llc | Method for the preparation of crystalline tetrahydrobenzothiepines |
JP2005518347A (ja) | 2001-11-02 | 2005-06-23 | ジー.ディー. サール エルエルシー | 頂端ナトリウム共依存性胆汁酸輸送(asbt)およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物 |
TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
GB0314079D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
JP2005518408A (ja) | 2001-12-29 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | 異常脂肪血症を治療するための、glp−1化合物と他の薬物との組み合わせ使用 |
GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
US20040014806A1 (en) | 2002-03-08 | 2004-01-22 | Pharmacia Corporation | Methods and compositions for lowering levels of blood lipids |
EP1490029A4 (en) | 2002-03-22 | 2006-02-22 | Ranbaxy Lab Ltd | DRUG DELIVERY SYSTEM WITH CONTROLLED RELEASE OF PRAVASTATIN |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
CA2497345C (en) | 2002-08-28 | 2008-10-14 | Asahi Kasei Pharma Corporation | Novel quaternary ammonium compounds |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
US7939061B2 (en) | 2003-02-28 | 2011-05-10 | Micropharma Limited | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
WO2004108067A2 (en) | 2003-04-03 | 2004-12-16 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
AU2008202120B2 (en) * | 2003-04-05 | 2009-12-17 | Albireo Ab | Use of an IBAT inhibitor for the treatment of prophylaxis of constipation |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
CN102077854A (zh) | 2003-10-16 | 2011-06-01 | 泰克康姆集团公司 | 具有降低的血糖应答的可消化性降低的碳水化合物食物 |
KR20070026392A (ko) | 2004-02-27 | 2007-03-08 | 아사히 가세이 파마 가부시키가이샤 | 신규 벤조티아제핀 및 벤조티에핀 화합물 |
WO2005082414A2 (en) | 2004-03-02 | 2005-09-09 | Astellas Pharma Inc. | Concomitant drugs of a sulfonamide and another therapeutic agent |
EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
US20050287178A1 (en) | 2004-06-23 | 2005-12-29 | Steed Barrie L | Diagnosis and treatment of heavy gallbladder densities |
JP4896480B2 (ja) | 2004-10-01 | 2012-03-14 | 第一三共ヘルスケア株式会社 | 陰イオン交換樹脂の粒子状組成物 |
US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
US20090131395A1 (en) | 2005-05-05 | 2009-05-21 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
US20080193543A1 (en) | 2005-05-17 | 2008-08-14 | Brown University Research Foundation | Drug Delivery Formulations For Targeted Delivery |
US20070237818A1 (en) | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
BRPI0616195A2 (pt) | 2005-09-20 | 2011-06-14 | Novartis Ag | uso de um inibidor de dpp-iv para reduzir eventos hipoglicÊmicos |
US20100286122A1 (en) | 2006-04-10 | 2010-11-11 | Kevin Belyk | CGRP Antagonist Salt |
GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
DE102006053637B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE102006053635B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
JP2010509252A (ja) | 2006-11-14 | 2010-03-25 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 改善された特性を有する新規な1,4−ベンゾチエピン−1,1−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用 |
DE102006053636B4 (de) | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung |
CA2676417C (en) | 2007-01-19 | 2016-06-28 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
ATE476176T1 (de) | 2007-03-02 | 2010-08-15 | Farnam Co Inc | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung |
SI2200588T1 (sl) | 2007-09-25 | 2019-08-30 | Solubest Ltd. | Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo |
US9295677B2 (en) | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
WO2010041268A2 (en) | 2008-09-02 | 2010-04-15 | Usv Limited | Crosslinked polymers |
EP2367554A4 (en) | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES |
US20110152204A1 (en) | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of Obesity or Diabetes with Bile Acid Sequestrants |
SI2538930T1 (sl) | 2010-02-23 | 2016-10-28 | Da Volterra | Formulacije za oralno dostavo adsorbentov v črevesju |
JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
US20120114588A1 (en) | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
SG189470A1 (en) | 2010-11-08 | 2013-05-31 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
CN104023718B (zh) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂 |
US9273085B2 (en) | 2012-05-07 | 2016-03-01 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative and use thereof for medical purposes |
US20140275090A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
JO3301B1 (ar) * | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
AU2015222754B2 (en) | 2014-02-27 | 2020-06-25 | Nusirt Sciences Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
EP3154523B1 (en) | 2014-06-16 | 2018-11-21 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
JP6581082B2 (ja) | 2014-06-25 | 2019-09-25 | Eaファーマ株式会社 | 固形製剤及びその安定化方法 |
CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
KR101674806B1 (ko) | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US9684018B2 (en) | 2014-11-19 | 2017-06-20 | Texas Instruments Incorporated | Current sense circuit that operates over a wide range of currents |
KR20160061492A (ko) | 2014-11-21 | 2016-06-01 | 삼성디스플레이 주식회사 | 휴대용 먼지 센서 및 이를 이용한 휴대전화 |
CN105985254B (zh) | 2015-02-17 | 2018-03-16 | 上海中科绿碳化工科技有限公司 | 一种制备甲酰胺类化合物的方法 |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
JP6954927B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
WO2017138876A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
ES2874669T3 (es) * | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
US11350844B2 (en) | 2016-11-23 | 2022-06-07 | Mayo Foundation For Medical Education And Research | System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography |
CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
MX2020009332A (es) | 2018-03-09 | 2020-10-08 | Elobix Ab | Proceso para la preparacion de elobixibat. |
US10428109B1 (en) | 2018-03-09 | 2019-10-01 | Elobix Ab | Process for the preparation of 1,5-benzothiazepine compounds |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
ES2942443T3 (es) | 2018-06-05 | 2023-06-01 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
CN112262130A (zh) | 2018-06-20 | 2021-01-22 | 阿尔比里奥公司 | 奥德昔巴特的结晶修饰物 |
US20200046758A1 (en) | 2018-08-09 | 2020-02-13 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US20200046757A1 (en) | 2018-08-09 | 2020-02-13 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations, and uses thereof |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
CN113453753A (zh) | 2019-02-06 | 2021-09-28 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
MX2021008981A (es) | 2019-02-06 | 2021-09-08 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar. |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
CA3129827A1 (en) | 2019-02-12 | 2020-08-20 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
PL4069360T3 (pl) | 2019-12-04 | 2024-04-29 | Albireo Ab | Związki benzotio(di)azepinowe i ich zastosowanie jako modulatory kwasów żółciowych |
CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
EP4188541A1 (en) | 2020-08-03 | 2023-06-07 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
AU2021390172A1 (en) | 2020-12-04 | 2023-06-22 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
-
2019
- 2019-06-20 CN CN201980039118.6A patent/CN112262130A/zh active Pending
- 2019-06-20 CA CA3100687A patent/CA3100687A1/en active Pending
- 2019-06-20 PE PE2020002088A patent/PE20210136A1/es unknown
- 2019-06-20 EP EP19734937.6A patent/EP3810581A1/en active Pending
- 2019-06-20 MX MX2020013839A patent/MX2020013839A/es unknown
- 2019-06-20 BR BR112020024479-1A patent/BR112020024479A2/pt unknown
- 2019-06-20 KR KR1020217001712A patent/KR20210024033A/ko unknown
- 2019-06-20 SG SG11202012151XA patent/SG11202012151XA/en unknown
- 2019-06-20 JO JOP/2020/0297A patent/JOP20200297A1/ar unknown
- 2019-06-20 KR KR1020217001711A patent/KR20210024032A/ko unknown
- 2019-06-20 JO JOP/2020/0299A patent/JOP20200299A1/ar unknown
- 2019-06-20 CR CR20210027A patent/CR20210027A/es unknown
- 2019-06-20 SG SG11202012170PA patent/SG11202012170PA/en unknown
- 2019-06-20 CN CN201980041077.4A patent/CN112312893A/zh active Pending
- 2019-06-20 US US16/477,160 patent/US11802115B2/en active Active
- 2019-06-20 WO PCT/SE2019/050602 patent/WO2019245448A1/en active Application Filing
- 2019-06-20 JP JP2020570778A patent/JP7448490B2/ja active Active
- 2019-06-20 AU AU2019290338A patent/AU2019290338A1/en active Pending
- 2019-06-20 WO PCT/SE2019/050603 patent/WO2019245449A1/en active Application Filing
- 2019-06-20 CR CR20210026A patent/CR20210026A/es unknown
- 2019-06-20 EP EP19735664.5A patent/EP3810084A1/en active Pending
- 2019-06-20 PE PE2020002089A patent/PE20210182A1/es unknown
- 2019-06-20 AU AU2019290337A patent/AU2019290337B2/en active Active
- 2019-06-20 CA CA3100691A patent/CA3100691A1/en active Pending
- 2019-06-20 TW TW108121584A patent/TWI823954B/zh active
- 2019-06-20 JP JP2020570784A patent/JP2021528416A/ja active Pending
- 2019-06-20 MX MX2020013774A patent/MX2020013774A/es unknown
- 2019-06-20 BR BR112020024461-9A patent/BR112020024461A2/pt unknown
- 2019-07-10 US US16/508,036 patent/US10975046B2/en active Active
-
2020
- 2020-10-07 US US17/065,245 patent/US11365182B2/en active Active
- 2020-12-14 PH PH12020552165A patent/PH12020552165A1/en unknown
- 2020-12-15 CO CONC2020/0015772A patent/CO2020015772A2/es unknown
- 2020-12-15 NI NI202000103A patent/NI202000103A/es unknown
- 2020-12-15 CO CONC2020/0015781A patent/CO2020015781A2/es unknown
- 2020-12-15 NI NI202000104A patent/NI202000104A/es unknown
- 2020-12-15 IL IL279464A patent/IL279464A/en unknown
- 2020-12-15 IL IL279468A patent/IL279468A/en unknown
- 2020-12-15 PH PH12020552168A patent/PH12020552168A1/en unknown
- 2020-12-18 CL CL2020003296A patent/CL2020003296A1/es unknown
- 2020-12-18 CL CL2020003295A patent/CL2020003295A1/es unknown
-
2021
- 2021-01-07 EC ECSENADI2021999A patent/ECSP21000999A/es unknown
- 2021-01-08 EC ECSENADI20211547A patent/ECSP21001547A/es unknown
-
2022
- 2022-05-13 US US17/744,429 patent/US20220281832A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013541584A (ja) * | 2010-11-08 | 2013-11-14 | アルビレオ アクチエボラグ | 肝疾患の処置用のibat阻害剤 |
JP2013545739A (ja) * | 2010-11-08 | 2013-12-26 | アルビレオ アクチエボラグ | Ibat阻害剤および胆汁酸結合剤を含む薬学的組み合わせ |
JP2014532662A (ja) * | 2011-10-28 | 2014-12-08 | ルメナ ファーマシューティカルズ,インク. | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
Non-Patent Citations (1)
Title |
---|
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 10, JPN6023012130, 2015, pages 255 - 274, ISSN: 0005025797 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021528415A (ja) | オデビキシバットの医薬製剤 | |
US20240130976A1 (en) | Pharmaceutical Formulation of Odevixibat | |
US11583539B2 (en) | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors | |
JP5405710B2 (ja) | タムスロシンを含む医薬ペレットおよびその製造方法 | |
TWI285116B (en) | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients | |
US20220331315A1 (en) | Dosage forms for tyk2 inhibitors | |
KR20150082203A (ko) | 엔잘루타마이드 제제 | |
HU229569B1 (hu) | Szelektív szerotoninújrafelvétel-gátlók szabályozott kibocsátású többrészecskés kiszerelései | |
WO2022101379A1 (en) | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) | |
US20220218699A1 (en) | New Pharmaceutical Formulation | |
CN116710100A (zh) | 用于治疗进行性家族性肝内胆汁淤积(pfic)的奥德昔巴特 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220615 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220615 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230703 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240229 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7448490 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |